Keros Therapeutics, Inc.

NasdaqGM:KROS Rapporto sulle azioni

Cap. di mercato: US$2.3b

Keros Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Keros Therapeutics diminuiranno del 5% all'anno, mentre si prevede che il fatturato annuo crescerà del 78.4% all'anno. Si prevede che l'EPS crescerà del 2.6% all'anno.

Informazioni chiave

-5.0%

Tasso di crescita degli utili

2.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili28.3%
Tasso di crescita dei ricavi78.4%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento22 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Nov 20
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23
Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10
We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Keros Therapeutics prices equity offering at $50

Nov 13

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:KROS - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/202614-252-252-21912
12/31/20250-231-223-17915
12/31/20240-195-200-15315
9/30/20241-182-143-140N/A
6/30/20240-168-146-144N/A
3/31/20240-160-137-135N/A
12/31/20230-153-127-125N/A
9/30/20230-142-123-120N/A
6/30/2023N/A-127-113-111N/A
3/31/2023N/A-116-105-103N/A
12/31/2022N/A-105-71-70N/A
9/30/202220-82-69-68N/A
6/30/202220-79-59-58N/A
3/31/202220-67-54-53N/A
12/31/202120-59-63-62N/A
9/30/20210-61-51-51N/A
6/30/20210-53-48-47N/A
3/31/2021N/A-49-40-39N/A
12/31/2020N/A-45-37-37N/A
9/30/20203-39-35-34N/A
6/30/20205-31-27-26N/A
3/31/20208-23-22-22N/A
12/31/201910-14-16-16N/A
12/31/201810-277N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che KROS rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di KROS ( 78.4% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di KROS ( 78.4% all'anno) crescerà più rapidamente di 20% all'anno.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di KROS è previsto essere elevato tra 3 anni


Scoprire le aziende in crescita